氧化应激相关通路在阿霉素诱导心脏毒性中的作用

doi:10.3760/cma.j.issn.1007-1245.2024.20.005

摘要/Abstract

摘要：

阿霉素（DOX）是一种强效化疗药物，常用于单独或联合治疗多种癌症，临床应用可能会导致严重的心脏毒性。氧化应激在阿霉素诱导心脏毒性（DIC）中发挥了重要作用。该综述总结了DIC中与氧化应激有关的信号通路，包括Nrf2/Keap1/ARE、Sirt1/p66Shc信号通路，以及一氧化氮合酶（NOS）、氮氧化物（NOX）、亚铁离子（Fe²⁺）在氧化应激中的作用，尝试从氧化应激的角度解释DIC的发生机制，并为DIC防治的药物研究提供理论依据或新思路。

关键词:

阿霉素, 心肌病, 氧化应激, 信号通路, 综述

Abstract:

Doxorubicin (DOX) is a potent chemotherapy drug commonly used alone or in combination to treat a variety of cancers. However, its clinical application may lead to severe cardiotoxicity. Oxidative stress has been found to play an important role in doxorubicin-induced cardiomyopathy (DIC). This review summarizes the signaling pathways related to oxidative stress in DIC, including Nrf2/Keap1/ARE and Sirt1/p66Shc signaling pathways, and the roles of nitric oxide synthase (NOS), nitric oxide (NOX), and Fe²⁺ in oxidative stress, in an attempt to explain the mechanism of DIC from the perspective of oxidative stress and to provide a theoretical basis or a new way of thinking for the pharmacological research of DIC prevention and treatment.

Key words:

Doxorubicin, Cardiomyopathy, Oxidative stress, Signaling pathway, Review

李洋程金凤魏景迅崔明丽程艳丽.

氧化应激相关通路在阿霉素诱导心脏毒性中的作用 [J]. 国际医药卫生导报, 2024, 30(20): 3369-3372.

Li Yang, Cheng Jinfeng, Wei Jingxun, Cui Mingli, Cheng Yanli.

Role of oxidative stress-related pathways in doxorubicin-induced cardiomyopathy [J]. International Medicine and Health Guidance News, 2024, 30(20): 3369-3372.

参考文献

[1] Johnson-Arbor K, Dubey R. Doxorubicin[M].Treasure Island (FL): StatPearls Publishing,2023:23.
[2] Johnson M, Keyes D.Anthracycline toxicity[M].Treasure Island (FL): StatPearls Publishing,2024:17.
[3] Wang X, Li C, Wang Q,et al. Tanshinone IIA restores dynamic balance of autophagosome/autolysosome in doxorubicin-induced cardiotoxicity via targeting beclin1/LAMP1[J]. Cancers (Basel), 2019,11(7):910.DOI: 10.3390/cancers11070910.
[4] Liang X, Wang S, Wang L,et al. Mitophagy inhibitor liensinine suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission[J]. Pharmacol Res, 2020,157:104846.DOI: 10.1016/j.phrs.2020.104846.
[5] Aryal B, Rao VA. Deficiency in cardiolipin reduces doxorubicin-induced oxidative stress and mitochondrial damage in human B-lymphocytes[J]. PLoS One, 2016,11(7):e0158376.DOI: 10.1371/journal.pone.0158376.
[6] de Oliveira BL, Niederer S. A biophysical systems approach to identifying the pathways of acute and chronic doxorubicin mitochondrial cardiotoxicity[J]. PLoS Comput Biol, 2016,12(11):e1005214.DOI: 10.1371/journal.pcbi.1005214.
[7] Mukhopadhyay P, Rajesh M, Bátkai S,et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro[J]. Am J Physiol Heart Circ Physiol, 2009,296(5):H1466-83.DOI: 10.1152/ajpheart.00795.2008.
[8] Yao Y, Xu X, Zhang G,et al. Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway[J]. Basic Res Cardiol, 107(3):267.DOI: 10.1007/s00395-012-0267-3.
[9] Sangomla S, Saifi MA, Khurana A,et al. Nanoceria ameliorates doxorubicin induced cardiotoxicity: possible mitigation via reduction of oxidative stress and inflammation[J]. J Trace Elem Med Biol, 2018,47:53-62.DOI: 10.1016/j.jtemb.2018.01.016.
[10] Yamamoto M, Kensler TW, Motohashi H. The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis[J]. Physiol Rev, 2018,98(3):1169-1203.DOI: 10.1152/physrev.00023.2017.
[11] Fão L, Mota SI, Rego AC. Shaping the Nrf2-ARE-related pathways in alzheimer's and parkinson's diseases[J]. Ageing Res Rev, 2019,54:100942.DOI: 10.1016/j.arr.2019.100942.
[12] Nordgren KKS, Wallace KB. Disruption of the Keap1/Nrf2-antioxidant response system after chronic doxorubicin exposure in vivo[J]. Cardiovasc Toxicol, 2020,20(6):557-570.DOI: 10.1007/s12012-020-09581-7.
[13] Yu X, Cui L, Zhang Z,et al. α-Linolenic acid attenuates doxorubicin-induced cardiotoxicity in rats through suppression of oxidative stress and apoptosis[J]. Acta Biochim Biophys Sin (Shanghai), 2013,45(10):817-826.DOI: 10.1093/abbs/gmt082.
[14] Bai Y, Chen Q, Sun YP,et al. Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation[J]. Cardiovasc Ther, 2017,35(5):1-12.DOI: 10.1111/1755-5922.12277.
[15] Kamble SM, Patil CR. Asiatic acid ameliorates doxorubicin-induced cardiac and hepato-renal toxicities with Nrf2 transcriptional factor activation in rats[J]. Cardiovasc Toxicol, 2018,18(2):131-141.DOI: 10.1007/s12012-017-9424-0.
[16] Sampaio SF, Branco AF, Wojtala A,et al. p66Shc signaling is involved in stress responses elicited by anthracycline treatment of rat cardiomyoblasts[J]. Arch Toxicol, 2016,90(7):1669-1684.DOI: 10.1007/s00204-015-1583-9.
[17] Hao C, Wu X, Zhou R,et al. Downregulation of p66Shc can reduce oxidative stress and apoptosis in oxidative stress model of marginal cells of stria vascularis in sprague dawley rats[J]. Drug Des Devel Ther, 2019,13:3199-3206.DOI: 10.2147/DDDT.S214918.
[18] Zhang H, Pang X, Yu H,et al. Genistein suppresses ox-LDL-elicited oxidative stress and senescence in HUVECs through the SIRT1-p66shc-foxo3a pathways[J]. J Biochem Mol Toxicol, 2022,36(1):e22939.DOI: 10.1002/jbt.22939.
[19] Yan H, Jihong Y, Feng Z,et al. Sirtuin 1-mediated inhibition of p66shc expression alleviates liver ischemia/reperfusion injury[J]. Crit Care Med, 2014,42(5):e373-381. DOI: 10.1097/CCM.0000000000000246.
[20] Wu YZ, Zhang L, Wu ZX,et al. Berberine ameliorates doxorubicin-induced cardiotoxicity via a SIRT1/p66Shc-mediated pathway[J]. Oxid Med Cell Longev, 2019,2019:2150394.DOI: 10.1155/2019/2150394.
[21] Zhu JN, Fu YH, Hu ZQ,et al. Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity[J]. Sci Rep, 2017,7(1):11879.DOI: 10.1038/s41598-017-12192-y.
[22] Priya LB, Baskaran R, Huang CY,et al. Neferine ameliorates cardiomyoblast apoptosis induced by doxorubicin: possible role in modulating NADPH oxidase/ROS-mediated NFκB redox signaling cascade[J]. Sci Rep, 2017,7(1):12283.DOI: 10.1038/s41598-017-12060-9.
[23] Cheng D, Chen L, Tu W,et al. Protective effects of valsartan administration on doxorubicin‑induced myocardial injury in rats and the role of oxidative stress and NOX2/NOX4 signaling[J]. Mol Med Rep, 2020,22(5):4151-4162.DOI: 10.3892/mmr.2020.11521.
[24] Zeng C, Duan F, Hu J,et al. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy[J]. Redox Biol,2020,34:101523.DOI: 10.1016/j.redox.2020.101523.
[25] Ma J, Wang Y, Zheng D,et al. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways[J]. Cardiovasc Res, 2013,97(1):77-87.DOI: 10.1093/cvr/cvs309.
[26] Zhang X, Hu C, Kong CY,et al. FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT[J]. Cell Death Differ, 2020,27(2):540-555.DOI: 10.1038/s41418-019-0372-z.
[27] Luu AZ, Chowdhury B, Al-Omran M,et al. Role of endothelium in doxorubicin-induced cardiomyopathy[J]. JACC Basic Transl Sci, 2018,3(6):861-870.DOI: 10.1016/j.jacbts.2018.06.005.
[28] Malik A, Bagchi AK, Vinayak K,et al. Vitamin C: historical perspectives and heart failure[J]. Heart Fail Rev, 2021,26(3):699-709. DOI: 10.1007/s10741-020-10036-y.
[29] Shi S, Chen Y, Luo Z,et al. Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy[J]. Cell Commun Signal, 2023,21(1):61.DOI: 10.1186/s12964-023- 01077-5.
[30] Akolkar G, Bagchi AK, Ayyappan P,et al. Doxorubicin-induced nitrosative stress is mitigated by vitamin C via the modulation of nitric oxide synthases[J]. Am J Physiol Cell Physiol, 2017,312(4):C418-C427.DOI: 10.1152/ajpcell.00356.2016.
[31] Huang WP, Yin WH, Chen JS,et al. Fenofibrate attenuates doxorubicin-induced cardiac dysfunction in mice via activating the eNOS/EPC pathway[J]. Sci Rep, 2021,11(1):1159.DOI: 10.1038/s41598-021-80984-4.
[32] Mu H, Liu H, Zhang J,et al. Ursolic acid prevents doxorubicin-induced cardiac toxicity in mice through eNOS activation and inhibition of eNOS uncoupling[J]. J Cell Mol Med, 2019,23(3):2174-2183. DOI: 10.1111/jcmm.14130.
[33] Octavia Y, Kararigas G, de Boer M,et al. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase[J]. J Cell Mol Med, 2017,21(12):3277-3287.DOI: 10.1111/jcmm.13231.
[34] Tadokoro T, Ikeda M, Ide T,et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity[J]. JCI Insight, 2020,5(9):e132747.DOI: 10.1172/jci.insight.132747.
[35] Imai H, Matsuoka M, Kumagai T,et al. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis[J]. Curr Top Microbiol Immunol, 2017,403:143-170.DOI: 10.1007/82_2016_508.
[36] Luo LF, Guan P, Qin LY,et al. Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling[J]. Mol Cell Biochem, 2021,476(7):2603-2611.DOI: 10.1007/s11010-021-04112-6.
[37] Milczarek A, Starzyński RR, Styś A,et al. A drastic superoxide-dependent oxidative stress is prerequisite for the down-regulation of IRP1: Insights from studies on SOD1-deficient mice and macrophages treated with paraquat[J]. PLoS One, 2017,12(5):e0176800.DOI: 10.1371/journal.pone.0176800.
[38] Fang X, Wang H, Han D,et al. Ferroptosis as a target for protection against cardiomyopathy[J]. Proc Natl Acad Sci U S A,2019,116(7):2672-2680.DOI: 10.1073/pnas.1821022116.
[39] Menon AV, Kim J. Iron promotes cardiac doxorubicin retention and toxicity through downregulation of the mitochondrial exporter ABCB8[J]. Front Pharmacol, 2022,13:817951.DOI: 10.3389/fphar.2022.817951.